Therapeutic Candidate or Device Autologous Human CD34+ HSC from Mobilized PBSC of Patients with Cystinosis Modified by Ex Vivo Transduction using the pCCL-CTNS Lentiviral Vector Indication Cystinosis ...

Research Objective Functional restoration following spinal cord injury using defined excitatory and inhibitory spinal interneuron progenitor cell transplantation Impact The development of a stem cell ...

La maladie coronarienne, entraînant un blocage du flux sanguin vers le cœur, est une cause majeure de crise cardiaque. L'âge et les blessures provoquent des changements structurels et fonctionnels ...

Research Objective We will identify SAR-CoV-2 T cell epitopes for vaccine development and specific TCRs for adoptive T cell therapy using a stem cell-based platform to generate specialized dendritic ...

Nos entristece profundamente saber del fallecimiento de un paciente que participaba en el ensayo clínico de fase 2 de Rocket Pharmaceuticals con RP-A501 para tratar la enfermedad de Danon. En nombre ...

SAN FRANCISCO, September 5, 2006 – The California Institute for Regenerative Medicine (CIRM) announced today that it has named Marcia Davey as Interim Financial Officer. The one-year appointment is ...

在基因工程领域，将大量遗传有效负载有效且稳定地插入包括人类诱导多能干细胞（iPSC）在内的原代人类细胞中仍然是一个艰巨的挑战。 传统方法，如逆转录病毒载体，由于半随机插入和基因沉默而面临局限性。 为了解决这些 ...

Clinical Trial Stage Projects Henry John Klassen A Phase 2 Study of the Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects with Retinitis Pigmentosa $5 ...

Trophoblast stem cells (TSCs) are crucial for developing the placenta, as they can produce all the cell types needed for its function. Culturing TSCs in the lab provides a valuable model to study how ...

We are deeply saddened to learn of the passing of a subject enrolled in Rocket Pharmaceuticals’ Phase 2 clinical trial of RP-A501 to treat Danon disease. On behalf of the California Institute for ...

La autorrenovación de las células madre embrionarias de ratón (mESC) se puede mantener mediante la activación del factor inhibidor de la leucemia (LIF)/transductor de señal y activador de la vía de ...

En 2024, le CIRM adopté un ensemble de recommandations clés de son Cadre d'allocation stratégique (CAS), un processus structuré et axé sur les données qui guide la priorisation du financement et des ...